RNS Number : 8981K
Renalytix PLC
05 November 2024
Renalytix plc
("Renalytix" or the "Company")
Directorate Change
Julian Baines MBE appointed as Executive Chairman
LONDON and NEW YORK, 5 November 2024 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces the appointment of Julian Baines MBE as Executive Chairman after shareholders approved the resolution
RNS Number : 8983K
Renalytix PLC
05 November 2024
TR-1: Standard form for notification of major holdings
1. Issuer Details
ISIN
GB00BYWL4Y04
Issuer Name
RENALYTIX PLC
UK or Non-UK Issuer
UK
2. Reason for Notification
An acquisition or disposal of voting rights
3. Details of person subject to the notification obligation
Name
Ruffer LLP
City of registered office (if applicable)
London
Country of registered office (if applicable)
United Kingdom
4. Details of the shareholder
Full name of shareholder(s) if different from the person(s) subject to the
RNS Number : 8880K
Renalytix PLC
04 November 2024
TR-1: Standard form for notification of major holdings
1. Issuer Details
ISIN
GB00BYWL4Y04
Issuer Name
RENALYTIX PLC
UK or Non-UK Issuer
UK
2. Reason for Notification
An acquisition or disposal of financial instruments; An event changing the breakdown of voting rights
3. Details of person subject to the notification obligation
Name
Pentwater Capital Management LP
City of registered office (if applicable)
Country of registered office (if applicable)
US
4. Details of the shareholder
Full name of
RNS Number : 4687K
Renalytix PLC
31 October 2024
Renalytix plc
("Renalytix" or the "Company")
Directorate Change
LONDON and NEW YORK, 31 October 2024 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that Dan Levangie, Non-Executive Director has stepped down from the Board of Renalytix, effective immediately, following the General Meeting today.
RNS Number : 4622K
Renalytix PLC
31 October 2024
Renalytix plc
("Renalytix" or the "Company")
Result of General Meeting
LONDON and NEW YORK, 31 October 2024 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that, at the General Meeting ("GM") held earlier today, all resolutions were passed. Further details of each of the resolutions are set out in the
RNS Number : 9446H Renalytix PLC 11 October 2024 Renalytix plc (" Renalytix " or the " Company ") Posting of Circular and Notice of General Meeting LONDON and NEW YORK , 11 October, 2024 ̶ Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics
RNS Number : 7887H Renalytix PLC 11 October 2024 Renalytix plc ("Renalytix" or the "Company") Director/PDMR Dealing LONDON and NEW YORK , 11 October 2024 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing
RNS Number : 7886H Renalytix PLC 11 October 2024 TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BYWL4Y04 Issuer Name RENALYTIX PLC UK or Non- UK Issuer UK 2. Reason for Notification An event changing the breakdown of voting rights 3.
RNS Number : 7884H Renalytix PLC 11 October 2024 TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BYWL4Y04 Issuer Name RENALYTIX PLC UK or Non- UK Issuer UK 2. Reason for Notification An event changing the breakdown of voting rights 3.
RNS Number : 5976H Renalytix PLC 09 October 2024 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing
RNS Number : 4004H Renalytix PLC 08 October 2024 Renalytix plc (" Renalytix " or the " Company ") Admission of Shares & Total Voting Rights Renalytix (AIM: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to
Renalytix plc American Depository Shares (ADSs) begin trading on OTCQB Venture Market under symbol “RNLXY” effective from Market Open on October 8, 2024 LONDON and NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro
RNS Number : 3346H Renalytix PLC 08 October 2024 Renalytix plc ("Renalytix" or the "Company") Commencement of trading on OTCQB in the United States Renalytix plc American Depository Shares (ADSs) begin trading on OTCQB Venture Market under symbol "RNLXY" effective from Market Open on
RNS Number : 4887G Renalytix PLC 01 October 2024 THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN (TOGETHER THIS "ANNOUNCEMENT") IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE
RNS Number : 4130G Renalytix PLC 01 October 2024 Renalytix plc ("Renalytix" or the "Company") Audited US GAAP financial results for the fiscal year ended 30 June 2024 LONDON and NEW YORK , 1 October, 2024 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in